MASON, Ohio--(BUSINESS WIRE)--Jul. 18, 2017--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has hired Salvatore (Sam) Privitera as
its Chief Technology Officer. Mr. Privitera will have responsibility for
Research and Development activities, as well as Operations, including
manufacturing, supply chain, and quality systems.
Most recently, Mr. Privitera served as Vice President of Research and
Development at Bard Medical (“BMD”), a division of C.R. Bard (NYSE:
BCR), where he helped grow BMD approximately 40% in 5 years to over $1
billion in revenue globally. He was responsible for a broad range of
clinical platforms including Therapeutic Hypothermia, Urologic Drainage,
Endourology, Brachytherapy, and Home Care where they impacted over 150
million patients on an annual basis. Additionally, he led multiple
discrete design centers, while delivering products into seven global
manufacturing centers and numerous supply partners. Prior to his role at
Bard, he worked for AtriCure as the Vice President of Engineering and
Product Development for ten years. During his tenure at AtriCure, the
company grew from a small startup into a public company, and he led
development of many platform technologies including the AtriClip product
line and the PMA approved Isolator® Synergy™ Ablation System. Prior to
AtriCure, Mr. Privitera worked at Ethicon Endo-Surgery, a Johnson and
Johnson company, in a variety of research, development and operations
roles.
“We are excited to have Sam joining us again at AtriCure,” said Mike
Carrel, President and Chief Executive Officer. “He is well recognized as
a creative, pragmatic and patient centric innovator with an eye towards
bringing high quality products to market efficiently. Additionally, he
obviously knows the company well, having served here previously, and he
brings a wealth of experience in the Afib space and a deep understanding
of the close link between product development and operations. Now is an
excellent time to bring him on as we look to continue to scale our
organization to support our growth objectives.”
“I am thrilled to be joining AtriCure at such an exciting time in the
company’s evolution,” said Mr. Privitera. “The company has not only done
a great job of bringing new technologies to market over the past several
years, it has scaled operations without any compromise in the quality
standards that have always been integral to its culture. With a broad
portfolio of products, and an exciting pipeline, the company is well
positioned to build on its leadership position in the treatment of
persistent and long-standing persistent Afib.”
“Since the beginning of 2014, we have brought eight new products to
market in the United States, inclusive of two acquisitions (Endoscopic
Technologies, Inc d/b/a Estech, and nContact, Inc.),” continued Mr.
Carrel. “These products have contributed meaningfully to our growth, and
I’m proud of our teams for their efforts. Sam is joining a high
performing team that has a proven track record.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage Exclusion System products are the most widely sold LAA
management devices worldwide. For more information, visit AtriCure.com
or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170718006040/en/
Source: AtriCure, Inc.
AtriCure, Inc.
Valerie Storch-Willhaus, 612-605-3311
Media
Relations
Director, Corporate Marketing and Communications
vstorch-willhaus@atricure.com
or
Andy
Wade, 513-755-4564
Investor Relations
Senior Vice President
and Chief Financial Officer
awade@AtriCure.com
